Zepp Health reported Q2 2026 revenue of $63.5M, up 6.9% year-over-year, driven by new product launches and improved product mix. Gross margin improved to 37.4%, but net loss widened to $11.3M due to foreign exchange headwinds and increased spending on R&D and marketing. The company launched new wearable products and plans to raise prices on its Bip family in 2027 to improve unit economics. For Q3 2026, Zepp expects revenue between $68M and $73M, reflecting ongoing supply recovery and product ramp-up.
Balchem Corporation reported strong Q3 2026 results with net sales of $290.7 million, up 8.6% year-over-year, and net earnings of $46.7 million, a 16% increase. Growth was driven by all three segments: Human Nutrition and Health, Animal Nutrition and...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
S&P Global Ratings has upgraded EssilorLuxottica's long-term credit rating to A+ with a stable outlook, recognizing the company's strong organic growth, solid cash flow, and robust balance sheet. The rating agency highlighted EssilorLuxottica's strat...
EssilorLuxottica announced that S&P Global Ratings has upgraded its long-term credit rating to A+ with a stable outlook. This upgrade recognizes the company's strong organic growth, consistent cash generation, and solid financial position. S&P also h...
Questrade now offers pre-market (7:30 am to 9:25 am ET) and post-market (4:00 pm to 4:15 pm ET) trading for equity options on 29 selected stocks and ETFs, including major names like AAPL and TSLA. This allows investors to respond to earnings reports ...
